Biogen Alzheimer’s Drug Coverage Threatens Minorities’ Access
Biogen Alzheimer’s Drug Coverage Threatens Minorities’ Access
Bloomberg Law | Jan 13, 2022
Recent Posts
- Medicare Limits Coverage of Controversial Alzheimer’s Drug to Those in Clinical Trials
- For People With Down Syndrome, A Longer Life, But Under A Cloud
- More Lawmakers Ratchet Up Pressure on CMS to Overturn Aduhelm Coverage Proposal
- National Coverage Determination May Limit Access to AD Treatment
- Medicare Proposal on Alzheimer’s Drug Draws Criticism From Drugmakers